CapsoVision | 8-K: FY2026 Q2 Revenue: USD 3.643 M
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 3.643 M.
EPS: As of FY2026 Q2, the actual value is USD -0.15, missing the estimate of USD -0.13.
EBIT: As of FY2026 Q2, the actual value is USD -7.481 M.
Second Quarter 2026 Financial Results
Revenue
CapsoVision, Inc. reported total revenue of $3.6 million for the second quarter of 2026, representing a 10% increase year-over-year compared to $3.3 million in the second quarter of 2025. This growth was primarily driven by a 13% increase in CapsoCam Plus capsules sold, partially offset by an approximately 3% decrease in the average selling price.
Gross Profit and Margin
Gross profit for the second quarter of 2026 was $1.9 million, an increase of $0.1 million or 3% compared to the second quarter of 2025. The gross margin for the period was 51%, down from 55% in the second quarter of 2025, attributed to pressure on selling prices and increased expenses from changes in U.S. government trade policies and tariffs.
Operating Expenses
Total operating expenses for the second quarter of 2026 were $9.5 million, an increase of $3.0 million from $6.462 million in the second quarter of 2025. This rise was mainly due to expenses associated with the colon pivotal study and other clinical trials, non-recurring engineering services for the Canon development project, costs of operating as a public company, and stock-based compensation. Selling and marketing expenses were $1,936 thousand in Q2 2026, up from $1,847 thousand in Q2 2025. Research and development expenses increased to $5,309 thousand in Q2 2026 from $3,392 thousand in Q2 2025. General and administrative expenses rose to $2,206 thousand in Q2 2026 from $1,223 thousand in Q2 2025.
Operating Loss
CapsoVision, Inc. reported an operating loss of - $7,580 thousand for the second quarter of 2026, compared to an operating loss of - $4,651 thousand in the second quarter of 2025.
Non-Operating Income
Total non-operating income, net, was $99 thousand in Q2 2026, up from $26 thousand in Q2 2025. This included net interest income of $82 thousand (compared to $37 thousand in Q2 2025) and other non-operating income (expense), net, of $17 thousand (compared to - $11 thousand in Q2 2025).
Net Loss
Net loss and comprehensive loss for the second quarter of 2026 was - $7,481 thousand, compared to - $4,625 thousand in the second quarter of 2025.
Six Months Ended June 30, 2026 Financial Results
Revenue
Net revenue for the six months ended June 30, 2026, was $6,435 thousand, compared to $6,098 thousand for the same period in 2025.
Gross Profit
Gross profit for the six months ended June 30, 2026, was $3,200 thousand, a decrease from $3,305 thousand in the prior year period.
Operating Expenses
Total operating expenses for the six months ended June 30, 2026, were $17,873 thousand, up from $13,338 thousand for the same period in 2025. Selling and marketing expenses were $4,027 thousand in 2026 vs. $3,808 thousand in 2025. Research and development expenses were $9,744 thousand in 2026 vs. $6,499 thousand in 2025. General and administrative expenses were $4,102 thousand in 2026 vs. $3,031 thousand in 2025.
Operating Loss
Operating loss for the six months ended June 30, 2026, was - $14,673 thousand, compared to - $10,033 thousand for the same period in 2025.
Net Loss
Net loss and comprehensive loss for the six months ended June 30, 2026, was - $14,514 thousand, compared to - $10,000 thousand for the same period in 2025.
Balance Sheet Highlights (as of June 30, 2026)
Cash and Cash Equivalents
Cash and cash equivalents totaled $9,077 thousand as of June 30, 2026, down from $10,112 thousand as of December 31, 2025.
Total Assets
Total assets were $18,569 thousand as of June 30, 2026, compared to $18,164 thousand as of December 31, 2025.
Total Liabilities
Total liabilities were $5,403 thousand as of June 30, 2026, compared to $4,904 thousand as of December 31, 2025.
Cash Flow Highlights (Six Months Ended June 30, 2026)
Net Cash Used in Operating Activities
Net cash used in operating activities was - $14,469 thousand for the six months ended June 30, 2026, compared to - $9,512 thousand for the same period in 2025.
Net Cash Used in Investing Activities
Net cash used in investing activities was - $48 thousand for the six months ended June 30, 2026, compared to - $70 thousand for the same period in 2025.
Net Cash Provided by Financing Activities
Net cash provided by financing activities was $13,509 thousand for the six months ended June 30, 2026, significantly up from $1,202 thousand for the same period in 2025, primarily due to $14,000 thousand in proceeds from a Private Placement.
Net Decrease in Cash and Cash Equivalents
The net decrease in cash and cash equivalents was - $1,008 thousand for the six months ended June 30, 2026, compared to a decrease of - $8,380 thousand for the same period in 2025.
Operational Metrics
As of June 30, 2026, CapsoCam Plus® has been used by over 176,000 patients.
Unique Financial Indicators
CapsoVision, Inc. entered into a sales agreement for an at-the-market equity offering program of up to $100 million with Cantor. The company may issue and sell shares of common stock with an aggregate offering price of up to $100,000,000 through the Agent, paying the Agent a commission of up to 3.0% of the aggregate gross proceeds from each sale of Placement Shares.
Outlook and Guidance
CapsoVision, Inc. anticipates FDA clearance of AI Highlights™ by the end of the third quarter of 2026, with a U.S. commercial launch expected shortly thereafter. The company’s pipeline continues to advance, with CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026. Additionally, ongoing enrollment continues for the CapsoCam UGI clinical study for pancreatic cancer detection.